Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Neogenomics Inc's Business Segments
Neogenomics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2025
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 181
Regions Reported
-
Revenue Share by Reportable Segment - Q2 FY2025
- Reportable0%
Revenue by Reportable Segment - Q2 FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 181 | - |
Revenue by Product & Service Category - Q2 FY2025
- Client direct billing72.4%
- Commercial insurance15.9%
- Medicare and Other Governmental11.8%
- Self Pay Services0%
Revenue by Product & Service Category - Q2 FY2025
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Client direct billing | $ 131 | 72.4% |
| Commercial insurance | $ 29 | 15.9% |
| Medicare and Other Governmental | $ 21 | 11.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Neogenomics Inc dataset.
Description of Neogenomics Inc
We run a network of cancer testing labs in the United States, Europe, and Asia. Our objective is to improve patient care by providing outstanding cancer-focused diagnostic services. Our aim is to be the worlds premier cancer testing and information company by providing unrivaled quality, great service, and cutting-edge solutions.
NeoGenomics Inc. is a leading provider of cancer-focused genetic testing services and is recognized for its commitment to advancing precision medicine. The company operates in several key segments, offering a wide range of products and services that cater to the diverse needs of healthcare providers and patients involved in cancer diagnostics and treatment. Below is an extensive overview of the segments, products, and services offered by NeoGenomics.
Segments
1. Clinical Services
- Anatomic Pathology: NeoGenomics provides comprehensive anatomic pathology services, including histopathology, cytopathology, and molecular pathology. These services involve the examination of tissue samples to diagnose cancer and other diseases.
- Molecular Diagnostics: This segment includes genetic tests that help identify mutations and variations in genes associated with different types of cancers. NeoGenomics offers next-generation sequencing (NGS) and other molecular techniques for precise diagnosis and treatment selection.
- Cytogenetics: NeoGenomics employs techniques such as karyotyping and fluorescence in situ hybridization (FISH) to analyze chromosomes in cancer cells, which helps in assessing chromosomal abnormalities often associated with malignancies.
2. Pharma Services
- Clinical Trial Support: The Pharma Services segment is dedicated to supporting biopharmaceutical companies in their drug development processes. NeoGenomics provides laboratory services, including biomarker testing and companion diagnostics, to assist in clinical trials.
- Customized Assay Development: NeoGenomics collaborates with pharmaceutical partners to design and develop assays tailored to specific research and clinical needs, enhancing the efficacy of drug candidates in targeted populations.
3. Revenue Cycle Management
- Billing Services: NeoGenomics offers comprehensive billing and collections services to healthcare providers, managing the medical billing cycle efficiently to optimize revenue.
- Coding Services: Their coding team ensures that the reports generated from tests are accurately coded to comply with regulations and maximize reimbursement.
Products and Services
1. Genetic Tests
- Oncology Panels: NeoGenomics provides a variety of NGS oncology panels that target specific gene mutations linked to various cancers. These panels help oncologists identify the most effective treatment options personalized to the patients tumor profile.
- Liquid Biopsy Tests: These non-invasive tests detect circulating tumor DNA (ctDNA) in blood samples, allowing for real-time monitoring of cancer progression and treatment response.
- Biomarker Testing: Services that identify specific biomarkers associated with various cancers, aiding oncologists in selecting the most appropriate therapies based on the molecular profile of the tumor.
2. Pathology Services
- Digital Pathology: Adoption of digital pathology technologies allows for remote viewing and consultation of pathology slides, facilitating collaboration among pathologists and improving diagnostic accuracy.
- Consultation Services: NeoGenomics provides expert consultation services for pathologists and oncologists, offering insights and interpretations of complex cases based on their extensive database and expertise.
3. Companion Diagnostics
- NeoGenomics collaborates with pharmaceutical companies to develop and validate companion diagnostic tests that help determine the efficacy of specific treatments for subsets of patients based on their genetic makeup.
4. Educational Services
- NeoGenomics actively engages in educating healthcare providers through webinars, workshops, and training sessions, disseminating knowledge about advancements in genetic testing and the implications for cancer care.
5. Research Collaborations
- The company partners with academic institutions and biopharma companies on research initiatives, aiming to uncover new insights into cancer genetics and improve diagnostic methodologies.
Conclusion
NeoGenomics stands out in the field of molecular diagnostics with a comprehensive suite of services and products dedicated to cancer management. By offering an extensive range of genetic testing, pathology services, and support for clinical research and drug development, the company plays a vital role in enhancing patient care through precision medicine. Their commitment to innovation, collaboration, and education ensures they remain at the forefront of cancer diagnostics and treatment solutions.
Segments
1. Clinical Services
- Anatomic Pathology: NeoGenomics provides comprehensive anatomic pathology services, including histopathology, cytopathology, and molecular pathology. These services involve the examination of tissue samples to diagnose cancer and other diseases.
- Molecular Diagnostics: This segment includes genetic tests that help identify mutations and variations in genes associated with different types of cancers. NeoGenomics offers next-generation sequencing (NGS) and other molecular techniques for precise diagnosis and treatment selection.
- Cytogenetics: NeoGenomics employs techniques such as karyotyping and fluorescence in situ hybridization (FISH) to analyze chromosomes in cancer cells, which helps in assessing chromosomal abnormalities often associated with malignancies.
2. Pharma Services
- Clinical Trial Support: The Pharma Services segment is dedicated to supporting biopharmaceutical companies in their drug development processes. NeoGenomics provides laboratory services, including biomarker testing and companion diagnostics, to assist in clinical trials.
- Customized Assay Development: NeoGenomics collaborates with pharmaceutical partners to design and develop assays tailored to specific research and clinical needs, enhancing the efficacy of drug candidates in targeted populations.
3. Revenue Cycle Management
- Billing Services: NeoGenomics offers comprehensive billing and collections services to healthcare providers, managing the medical billing cycle efficiently to optimize revenue.
- Coding Services: Their coding team ensures that the reports generated from tests are accurately coded to comply with regulations and maximize reimbursement.
Products and Services
1. Genetic Tests
- Oncology Panels: NeoGenomics provides a variety of NGS oncology panels that target specific gene mutations linked to various cancers. These panels help oncologists identify the most effective treatment options personalized to the patients tumor profile.
- Liquid Biopsy Tests: These non-invasive tests detect circulating tumor DNA (ctDNA) in blood samples, allowing for real-time monitoring of cancer progression and treatment response.
- Biomarker Testing: Services that identify specific biomarkers associated with various cancers, aiding oncologists in selecting the most appropriate therapies based on the molecular profile of the tumor.
2. Pathology Services
- Digital Pathology: Adoption of digital pathology technologies allows for remote viewing and consultation of pathology slides, facilitating collaboration among pathologists and improving diagnostic accuracy.
- Consultation Services: NeoGenomics provides expert consultation services for pathologists and oncologists, offering insights and interpretations of complex cases based on their extensive database and expertise.
3. Companion Diagnostics
- NeoGenomics collaborates with pharmaceutical companies to develop and validate companion diagnostic tests that help determine the efficacy of specific treatments for subsets of patients based on their genetic makeup.
4. Educational Services
- NeoGenomics actively engages in educating healthcare providers through webinars, workshops, and training sessions, disseminating knowledge about advancements in genetic testing and the implications for cancer care.
5. Research Collaborations
- The company partners with academic institutions and biopharma companies on research initiatives, aiming to uncover new insights into cancer genetics and improve diagnostic methodologies.
Conclusion
NeoGenomics stands out in the field of molecular diagnostics with a comprehensive suite of services and products dedicated to cancer management. By offering an extensive range of genetic testing, pathology services, and support for clinical research and drug development, the company plays a vital role in enhancing patient care through precision medicine. Their commitment to innovation, collaboration, and education ensures they remain at the forefront of cancer diagnostics and treatment solutions.